 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- Zolinza (vorinostat) / Merck (MSD)
Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4829;
P1
The safety profile of ABT-301 was superior to known HDAC inhibitors with only predictable HDAC inhibitor-related toxicities observed but no cardiac toxicity, neutropenia, nor lymphopenia elicited. Non-clinical and clinical results suggested the potential clinical development of ABT-301 in combination with myelosuppressive agents and immunotherapies.
- | MPT0E028 / Taipei Municipal Wanfang Hospital
Preclinical, Journal, Epigenetic controller: A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model. (Pubmed Central) - Jun 8, 2022
Our study showed that the potent HDAC inhibitor MPT0E028 reduced the severity and inflammation of emphysema with improvement in lung function, which could be regulated by Hippo signaling pathway. The MPT0E028 may have therapeutic potential for emphysema.
- | rocilinostat (ACY-1215) / Regenacy, BMS
Preclinical, Journal: Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury. (Pubmed Central) - Nov 26, 2020
Our research indicated that HDAC6 inhibition by ACY1215 might reduce infarct size in rats with cardiac IR injury possibly through modulating HIF-1α expression. TGF-β and CRP should be useful biomarkers to monitor the use of ACY1215 in cardiac IR injury.
- | MPT0E028 / Taipei Municipal Wanfang Hospital
Journal: Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. (Pubmed Central) - May 27, 2020
The synergistic anti-survival effect of the combination was suggested to occur via compensation of the MEK inhibitor for activated ERK. Our results indicate that this combination strategy could benefit patients with pancreatic cancer beyond K-Ras status.
- | MPT0E028 / Anbogen Therap, Formosa Labs
Trial completion, Trial completion date, Metastases: Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment (clinicaltrials.gov) - Apr 11, 2019
P1, N=23, Completed, Sponsor: Taipei Medical University
Our results indicate that this combination strategy could benefit patients with pancreatic cancer beyond K-Ras status. Recruiting --> Completed | Trial completion date: Jun 2019 --> Jan 2019
- | MPT0E028 / Anbogen Therap, Formosa Labs
Trial completion date, Trial primary completion date, Metastases: Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment (clinicaltrials.gov) - Sep 14, 2018
P1, N=30, Recruiting, Sponsor: Taipei Medical University
Recruiting --> Completed | Trial completion date: Jun 2019 --> Jan 2019 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- | MPT0E028 / Anbogen Therap, Formosa Labs
Trial primary completion date, Metastases: Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment (clinicaltrials.gov) - Jun 2, 2017
P1, N=30, Recruiting, Sponsor: Taipei Medical University
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- MPT0E028 / Anbogen Therap, Formosa Labs
Trial primary completion date, Metastases: Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment (clinicaltrials.gov) - Nov 6, 2015
P1, N=30, Recruiting, Sponsor: Taipei Medical University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: May 2016 --> Dec 2016
- MPT0E028 / Anbogen Therap, Formosa Labs
New P1 trial, Metastases: Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment (clinicaltrials.gov) - Jan 30, 2015
P1, N=30, Recruiting, Sponsor: Taipei Medical University